Research programme: cancer therapeutics - Onxeo

Drug Profile

Research programme: cancer therapeutics - Onxeo

Alternative Names: BA-016; Zyxin targeted cancer therapeutics - Onxeo; Zyxine

Latest Information Update: 03 Sep 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioAlliance Pharma
  • Developer Onxeo SA
  • Class
  • Mechanism of Action Actin stimulants; Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 Sep 2014 Discontinued - Preclinical for Cancer in France (unspecified route)
  • 01 Aug 2014 TopoTarget has merged with BioAlliance Pharma to form Onxeo SA
  • 02 Feb 2011 Preclinical development is ongoing in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top